A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.

Recursion Pharmaceuticals, Inc. RXRX

Weak (early) Emerging Frontier sector · Recursion — AI-driven drug-discovery platform, pre-profit biotech.

Key quality signals

Revenue growth (YoY)11%

Gross margin-34.4%

Gross profits / assets-0.02

Rule of 40-871.9

Net margin-882.9%

Cash runway (months)24.5

PEG—

P/S21.7

Risk flags

Burning cash — operating margin is negative.Thin gross margin — keeps little of each sales dollar (judge it against its industry).Heavy dilution (~31%/yr) — top-decile share issuers have historically underperformed.

Insider & analyst context

Insider 90-day: 0 cluster buyer(s), 5 seller(s). Insider selling is routine diversification, not a bearish signal.
Analyst mix: 2 strong-buy / 6 buy / 6 hold / 0 sell. Ratings are context, not a price target.

Similar Emerging Frontier names

Centrus Energy Corp.BigBear.ai Holdings, Inc.Kratos Defense & Security Solutions, Inc.Nano Nuclear Energy IncOuster, Inc.SoundHound AI, Inc.

← All Emerging Frontier names · Open RXRX in the interactive screener →

Data as of 2026-06-09 22:43 (end-of-day). How grades are computed →